Messenger RNA specialist Moderna's R&D spend sunk by nearly a third last year, a drop attributed in part to the wind-down of major phase 3 respiratory trials. In 2025, Moderna spent $3.1 billion on ...
An experimental medicine from BridgeBio Pharma, the San Francisco-area biotechnology company, has succeeded in a late-stage clinical trial as a treatment for the most common type of dwarfism, results ...
The letter amounts to another new regulatory hurdle in the U.S. for Moderna, whose mRNA technology helped end the COVID-19 pandemic but has since become a target of federal health officials under the ...
The Food and Drug Administration rejected a gene therapy Regenxbio has been developing for a rare disease called Hunter syndrome, in a decision that marks the latest blow for a field that has seen ...
The stock price of BridgeBio plunged 15% Thursday as Pfizer’s reported decision to withdraw a tafamidis patent in the European Union triggered fears of earlier generic entry in the blockbuster ...
On Page 76 of the 1959 Hibbing, Minnesota, high school yearbook, a certain member of the senior class is quoted as vowing “to join ‘Little Richard’” after graduation. That didn’t happen. Once this ...
The pacer has played nine T20Is, taking nine wickets at an average of 33.00, and a strike rate of 18.6. The recent T20I series against New Zealand, which ended on January 31 with India winning 4-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results